Induction chemotherapy and concurrent chemoradiotherapy for larynx preservation in laryngeal and hypopharyngeal cancerStrojan, Primož (Avtor) Plavc, Gaber (Avtor) Šifrer, Robert (Avtor) Jereb, Simona (Avtor) Lanišnik, Boštjan (Avtor) Kokalj, Marko (Avtor) Grošelj, Aleš (Avtor) Grašič-Kuhar, Cvetka (Avtor) induction chemotherapychemoradiotherapyarynx preservationTo test the hypothesis that clinical tumor response after a single cycle of induction chemotherapy (ICT) can reliably differentiate between chemo-/radiosensitive and resistant tumors in the larynx preservation setting. Patients and methods Treatment consisted of docetaxel/cisplatin/5-fluorouracil (TPF) ICT followed by concurrent chemoradiotherapy (cCRT) with weekly cisplatin. The response of the primary tumor was assessed by transnasal endoscopy after the first ICT cycle. Results 37/39 (95%) patients with laryngeal (46%) or hypopharyngeal (54%) carcinoma responded to one cycle of ICT, and two patients were referred for salvage surgery. Laryngectomy-free survival at 2 and 5 years was 87% and 75%, respectively. The corresponding rates for locoregional control (and also for disease-free survival) were 79% and 70% and for overall survival 92% and 82%. Conclusions Clinical assessment of tumor response to one cycle of TPF ICT serves as a valid and easy-to-use predictor of tumor sensitivity to platinum-based cCRT.Association of Radiology and Oncology20252026-01-15 03:48:02Neznano25286Ljubljanaslby Authors